COUR Pharma

102 posts

COUR Pharma banner
COUR Pharma

COUR Pharma

@CourPharma

Reprogramming the immune system to restore health in people suffering from autoimmune diseases

United States Katılım Ocak 2014
73 Takip Edilen196 Takipçiler
COUR Pharma
COUR Pharma@CourPharma·
March is #AutoimmuneAwarenessMonth and recognizing the millions living with #AutoimmuneDiseases. At COUR, we’re advancing antigen-specific tolerance therapies designed to address the root cause of autoimmune disease-not just their symptoms. More here: ttps://bit.ly/3PxAGnn
English
0
0
0
19
COUR Pharma
COUR Pharma@CourPharma·
One-year data from the Phase 2a trial of our investigational therapy CNP-104 show sustained benefit in #PrimaryBiliaryCholangitis (#PBC): · Improved ALP and bilirubin levels · Durable effects across liver stiffness · Favorable safety and tolerability More: bit.ly/4lcgO5g
English
0
0
0
57
COUR Pharma
COUR Pharma@CourPharma·
Our VP of Research, Adam Elhofy, PhD, will present at the 9th Annual Antigen-Specific Immune Tolerance Summit. He will highlight clinical signatures of tolerance observed in our program for #PrimaryBiliaryCholangitis. Learn more: bit.ly/3MMZLJQ
COUR Pharma tweet media
English
0
0
0
35
COUR Pharma
COUR Pharma@CourPharma·
Our recent publication in @ScienceMagazine defines how COUR nanoparticles (CNPs) induce antigen-specific immune tolerance by activating the same pathway the immune system uses to maintain self-tolerance during apoptotic cell clearance. Read more: bit.ly/4k8NMTt
COUR Pharma tweet media
English
1
0
3
56
COUR Pharma
COUR Pharma@CourPharma·
We are enrolling adults in a #ClinicalTrial of CNP-106, an investigational, disease-specific immune therapy for #MyastheniaGravis. The study explores a targeted immune approach that aims to improve MG symptoms. Learn more: bit.ly/4pDKPLP
COUR Pharma tweet media
English
0
0
2
56
COUR Pharma
COUR Pharma@CourPharma·
We are a proud partner of the 9th Annual ASIT Summit. We look forward to connecting with our peers and discussing the latest innovations in immune tolerance in March 2026. Our VP of Research, Adam Elhofy, PhD, will present. Details: bit.ly/3MMZLJQ
COUR Pharma tweet mediaCOUR Pharma tweet media
English
1
0
0
43
COUR Pharma
COUR Pharma@CourPharma·
We recently hosted the @ChiBiomed Entrepreneurial Fellows at our office. We discussed careers in biopharma and dug into the science behind our approach to antigen-specific immune tolerance. We are grateful for our collaboration and inspired by these future industry leaders.
COUR Pharma tweet media
English
0
0
0
37
COUR Pharma
COUR Pharma@CourPharma·
We’re testing investigational therapy CNP-103 in a Phase 1/2 trial in patients with #Type1Diabetes as a novel approach to maintain insulin production by slowing the immune attack on beta cells. Learn more: bit.ly/40ptZqa
English
0
0
0
46
COUR Pharma
COUR Pharma@CourPharma·
We’re proud that COUR has been named one of @BioSpace’s 2026 Best Places to Work! Our team of curious, driven individuals bring creativity & collaboration to everything we do as we redefine what’s possible in the fight against autoimmune disease: bit.ly/4hRgqYc
COUR Pharma tweet media
English
0
0
0
37
COUR Pharma
COUR Pharma@CourPharma·
Don’t miss our two posters at @AASLDTweets’ #TLM25. The posters highlight data for our investigational tolerogenic therapy, CNP-104, which is being evaluated for the treatment of primary biliary cholangitis (PBC). Learn more about CNP-104 here: bit.ly/3Wty9Lo
COUR Pharma tweet mediaCOUR Pharma tweet mediaCOUR Pharma tweet media
English
1
1
1
158
COUR Pharma
COUR Pharma@CourPharma·
Team COUR was proud to join @BreakthroughT1D’s Chicago Walk last month in support of the #Type1Diabetes community. Together, we’re walking toward a future where innovative science and collective action will change lives for people with T1D.
English
0
0
0
37
COUR Pharma
COUR Pharma@CourPharma·
Our CMO, Paul Peloso, MD, is featured in @t1d_strong_org’s latest blog post. Read more about our work to advance an antigen-specific immune tolerance therapy that could represent a true disease-modifying treatment for those newly diagnosed with T1D: bit.ly/4gZX8zg
COUR Pharma tweet media
English
1
0
1
66
COUR Pharma
COUR Pharma@CourPharma·
Congratulations to Darshil Patel, PhD, Director of R&D, who was named to @BioSpace’s inaugural 40 Under 40 list. Read how Darshil is leading teams as we advance our antigen-specific immune tolerance programs into the clinic for several autoimmune disease: bit.ly/4pUMJZT
COUR Pharma tweet media
English
0
0
0
35
COUR Pharma
COUR Pharma@CourPharma·
Last week we welcomed the @IAmBiotech team to our new office and lab spaces as part of #BIOontheAmericanRoad. We connected with @IllinoisBiotech and shared how we are advancing the next generation of disease-modifying therapies for #AutoimmuneDiseases.
Biotechnology Innovation Organization@IAmBiotech

#BIOontheAmericanRoad has officially arrived in Chicago, and the first stop included a tour of @CourPharma’s new office and lab spaces. COUR leadership discussed how the biotech leader is developing the next generation of disease-modifying therapies for people living with autoimmune disease. BIO President and CEO John F. Crowley also met with John Conrad, CEO of @IllinoisBiotech, an Illinois BIO affiliate and a representative of the Illinois Department of Commerce and Economic Opportunity.

English
0
0
0
22
COUR Pharma
COUR Pharma@CourPharma·
Our CEO, Dannielle Appelhans, recently participated in a panel at the Angelini Ventures 2025 Summit in Rome. She joined fellow healthcare leaders to discuss clinical development and market access. Thank you to the Angelini Ventures team for the invitation.
COUR Pharma tweet media
English
1
0
1
41
COUR Pharma
COUR Pharma@CourPharma·
We look forward to hosting John F. Crowley, President and CEO of @IAmBiotech, during his visit to Chicago as part of the #BIOontheAmericanRoad tour.
Biotechnology Innovation Organization@IAmBiotech

#BIOontheAmericanRoad is headed to the Windy City. During the tour’s fourth official stop, BIO President & CEO John F. Crowley will meet with clinical-stage biotech leader @CourPharma and local patient advocates to discuss the unprecedented growth in Illinois’ bioscience industry - and its promise of delivering innovative treatments to patients faster.

English
0
0
1
31

Keşfet

@ImmunologyAAI @ScienceMagazine @ChiBiomed @MyastheniaOrg @BioSpace @AASLDTweets @BreakthroughT1D @t1d_strong_org